These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 26558647)

  • 1. The role of adjuvant therapy in uterine leiomyosarcoma.
    Ducie JA; Leitao MM
    Expert Rev Anticancer Ther; 2016; 16(1):45-55. PubMed ID: 26558647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
    Friedman CF; Hensley ML
    Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
    Ricci S; Stone RL; Fader AN
    Gynecol Oncol; 2017 Apr; 145(1):208-216. PubMed ID: 28209496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
    Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
    Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
    Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uterine leiomyosarcoma metastasizing to the heart.
    Tunio MA; Al-Asiri M; Fareed MM
    J Coll Physicians Surg Pak; 2014 Mar; 24 Suppl 1():S20-1. PubMed ID: 24717993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single institute.
    Kodama K; Sonoda K; Kijima M; Yamaguchi S; Yagi H; Yasunaga M; Ohgami T; Onoyama I; Kaneki E; Okugawa K; Yahata H; Ohishi Y; Oda Y; Kato K
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e63-e67. PubMed ID: 31721462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
    Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
    Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of advanced uterine leiomyosarcoma.
    Hyman DM; Grisham RN; Hensley ML
    Curr Opin Oncol; 2014 Jul; 26(4):422-7. PubMed ID: 24840518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine leiomyosarcoma: A review of the literature and update on management options.
    Roberts ME; Aynardi JT; Chu CS
    Gynecol Oncol; 2018 Dec; 151(3):562-572. PubMed ID: 30244960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic treatment in adult uterine sarcomas.
    Desar IME; Ottevanger PB; Benson C; van der Graaf WTA
    Crit Rev Oncol Hematol; 2018 Feb; 122():10-20. PubMed ID: 29458779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
    Diggs A; Sia TY; Huang Y; Gockley A; Melamed A; Khoury-Collado F; St Clair C; Hou JY; Hershman DL; Wright JD
    Gynecol Oncol; 2022 Aug; 166(2):308-316. PubMed ID: 35660331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the treatment of uterine leiomyosarcoma in the Medicare population.
    Foley OW; Rauh-Hain JA; Clemmer J; Clark RM; Hall T; Diver EJ; Schorge JO; del Carmen MG
    Int J Gynecol Cancer; 2015 Mar; 25(3):453-8. PubMed ID: 25628107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of treatment of uterine leiomyosarcomas.
    Reed N
    Curr Oncol Rep; 2013 Dec; 15(6):581-7. PubMed ID: 24136566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy.
    Yang Q; Madueke-Laveaux OS; Cun H; Wlodarczyk M; Garcia N; Carvalho KC; Al-Hendy A
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine sarcomas--recent progress and future challenges.
    Seddon BM; Davda R
    Eur J Radiol; 2011 Apr; 78(1):30-40. PubMed ID: 21247711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.